Erika N. Cline
Acumen Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, Computational Drug Discovery Methods, Metabolomics and Mass Spectrometry Studies, Advanced Proteomics Techniques and Applications
Most-Cited Works
- → The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade(2018)836 cited
- → Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling(2012)55 cited
- → Paclitaxel-Conjugated PAMAM Dendrimers Adversely Affect Microtubule Structure through Two Independent Modes of Action(2013)55 cited
- → ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease(2022)46 cited
- → A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers(2017)36 cited
- → ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan(2022)25 cited
- Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station.(2017)
- → A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer's‐associated pathologies(2018)25 cited
- → Elucidating Molecular Mass and Shape of a Neurotoxic Aβ Oligomer(2014)24 cited
- → Delineating Anopheles gambiae coactivator associated arginine methyltransferase 1 automethylation using top–down high resolution tandem mass spectrometry(2009)22 cited